scholarly journals A Technical Note

2013 ◽  
Vol 19 (1) ◽  
pp. 27-34 ◽  
Author(s):  
V.M. Pereira ◽  
A. Marcos-Gonzalez ◽  
I. Radovanovic ◽  
P. Bijlenga ◽  
A.P. Narata ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Young Patient ◽  
Arteriovenous Malformations ◽  
Technical Note ◽  
Cerebral Arteriovenous Malformations ◽  
Arterial Access ◽  
Therapeutic Method ◽  
Endovascular Approach ◽  
Ruptured Avm ◽  
Transvenous Approach

Ruptured cerebral arteriovenous malformations (AVMs) usually require treatment to avoid re-bleeding. Depending on the angioarchitecture and center strategy, the treatment can be surgical, endovascular, radiosurgical or combined methods. The classic endovascular approach is transarterial, but sometimes it is not always applicable. The transvenous approach has been described as an alternative for the endovascular treatment of small AVMs when arterial access or another therapeutic method is not possible. This approach can be considered when the nidus is small and if there is a single draining vein. We present a technical note on a transvenous approach for the treatment of a ruptured AVM in a young patient.

scholarly journals A proposed grading system for endovascular treatment of cerebral arteriovenous malformations: Buffalo score

2015 ◽  
Vol 6 (1) ◽  
pp. 3 ◽  
Author(s):  
EladI Levy ◽  
TravisM Dumont ◽  
Peter Kan ◽  
KennethV Snyder ◽  
LNelson Hopkins ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Grading System ◽  
Cerebral Arteriovenous Malformations

scholarly journals Hemorrhagic Complications after Endovascular Treatment of Cerebral Arteriovenous Malformations

2014 ◽  
Vol 35 (5) ◽  
pp. 978-983 ◽  
Author(s):  
H. Baharvahdat ◽  
R. Blanc ◽  
R. Termechi ◽  
S. Pistocchi ◽  
B. Bartolini ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Cerebral Arteriovenous Malformations ◽  
Hemorrhagic Complications

scholarly journals Cerebral Arteriovenous Malformations with Associated Arterial Aneurysms: Hemodynamic and Therapeutic Considerations

1988 ◽  
Vol 15 (2) ◽  
pp. 130-134 ◽  
Author(s):  
Douglas Kondziolka ◽  
Bruce J. Nixon ◽  
Pierre Lasjaunias ◽  
Pierre Lasjaunias ◽  
William S. Tucker ◽  
...  
Keyword(s):  
Blood Flow ◽  
Arteriovenous Malformation ◽  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Local Blood Flow ◽  
Cerebral Arteriovenous Malformations ◽  
Regional Hemodynamics ◽  
The Common ◽  
Arterial Aneurysms ◽  
Therapeutic Considerations

ABSTRACT:The common vascular anomalies of cerebral aneurysm and arteriovenous malformation may exist independently, or together as part of a closely related hemodynamic pairing. Resection or embolization of an AVM may be followed by a decrease in local blood flow, and lead to regression of a suitably situated proximal aneurysm. However, aneurysms located outside the angioarchitecture of the AVM, which remain flow-unrelated to the malformation, will likely not regress, and may in fact enlarge. Two cases are presented which demonstrate these vascular relationships, in order to better understand the regional hemodynamics of these anomalies prior to surgical or endovascular treatment planning.

Embolic Agents and Microcatheters for Endovascular Treatment of Cerebral Arteriovenous Malformations

2020 ◽  
Vol 141 ◽  
pp. 383-388
Author(s):  
Matthew J. Triano ◽  
Jacques Lara-Reyna ◽  
Alexander J. Schupper ◽  
Kurt A. Yaeger
Keyword(s):  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Cerebral Arteriovenous Malformations ◽  
Embolic Agents

Morbidity and mortality associated with sequential flow reduction embolization technique of cerebral arteriovenous malformations using n-butyl cyanoacrylate

2020 ◽  
pp. neurintsurg-2020-016223
Author(s):  
Alfred P See ◽  
Mahmoud H Mohammaden ◽  
Mark Rizko ◽  
Christopher J Stapleton ◽  
Sepideh Amin-Hanjani ◽  
...  
Keyword(s):  
Arteriovenous Malformations ◽  
Endovascular Embolization ◽  
Morbidity And Mortality ◽  
Treatment Modalities ◽  
Cerebral Arteriovenous Malformations ◽  
Major Morbidity ◽  
Factors Affecting ◽  
Flow Reduction ◽  
Ruptured Avm ◽  
Targeting Strategy

BackgroundEndovascular embolization of cerebral arteriovenous malformations (AVM) with liquid n-butyl cyanoacrylate (n-BCA) serves multiple purposes including AVM occlusion and flow reduction in preparation for other treatment modalities. The objective was to study the clinical, structural, and angiographic factors affecting complications associated with AVM treatment by sequential n-BCA embolizations for nidal occlusion versus quantitative flow reduction in preparation for surgical resection or radiosurgery.MethodsWe performed a retrospective review of all patients who underwent endovascular embolization of cerebral AVM at our institution between 1998 and 2019, during which time the technique of traditional embolization evolved to a strategy of targeted sequential flow reduction guided by serial flow imaging based on quantitative magnetic resonance angiography, in conjunction with a shift away from nidal penetration.ResultsAmong 251 patients, 47.8% of patients presented with ruptured AVM. On average, each patient underwent 2.4 embolizations, for a total of 613 sessions. Major morbidity related to embolization occurred in 18 (7.2%) patients, but this occurred disproportionately in the traditional embolization strategy (n=16, 8%) in contrast with the flow-targeting strategy (n=2, 3.8%). Four patients (1.6%) died in the overall group, and these all occurred with the traditional embolization strategy (2% of 199 patients); no deaths occurred in the flow-targeting strategy (n=52).ConclusionEmbolization with n-BCA targeted to sequential flow reduction and feeder occlusion with limited nidal penetration prior to definitive surgical or radiosurgical treatment can be safely performed with low overall morbidity and mortality.

The Bulgarian Experience in Endovascular Treatment of Cerebral Arteriovenous Malformations

2018 ◽  
Author(s):  
Stanimir Sirakov ◽  
Alexander Sirakov ◽  
Krasimir Minkin ◽  
Hristo Hristov ◽  
Vasil Karakostov
Keyword(s):  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Cerebral Arteriovenous Malformations

scholarly journals Endovascular treatment of small cerebral arteriovenous malformations as a primary therapy

2018 ◽  
Vol 83 ◽  
pp. 143-149 ◽  
Author(s):  
Damian Kocur ◽  
Nikodem Przybyłko ◽  
Mariusz Hofman ◽  
Tomasz Jamróz ◽  
Aleksandra Ignatowicz ◽  
...  
Keyword(s):  
Endovascular Treatment ◽  
Arteriovenous Malformations ◽  
Primary Therapy ◽  
Cerebral Arteriovenous Malformations

scholarly journals Transvenous Approach for the Treatment of cerebral Arteriovenous Malformations (TATAM): Study protocol of a randomised controlled trial

2019 ◽  
Vol 25 (3) ◽  
pp. 305-309 ◽  
Author(s):  
Robert Fahed ◽  
Tim E Darsaut ◽  
Charbel Mounayer ◽  
René Chapot ◽  
Michel Piotin ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Arteriovenous Malformation ◽  
Arteriovenous Malformations ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Cerebral Arteriovenous Malformations ◽  
Clinical Trial Registration ◽  
Transarterial Embolisation ◽  
Randomised Controlled ◽  
Transvenous Approach

Background Transvenous embolisation is a promising technique but the benefits remain uncertain. We hypothesised that transvenous embolisation leads to a higher rate of arteriovenous malformation angiographic occlusion than transarterial embolisation. Methods The Transvenous Approach for the Treatment of cerebral Arteriovenous Malformations (TATAM) is an investigator initiated, multicentre, prospective, phase 2, randomised controlled clinical trial. To test the hypothesis that transvenous embolisation is superior to transarterial embolisation for arteriovenous malformation obliteration, 76 patients with arteriovenous malformations considered curable by up to two sessions of endovascular therapy will be randomly allocated 1:1 to treatment with either transvenous embolisation (with or without transarterial embolisation) (experimental arm) or transarterial embolisation alone (control arm). The primary endpoint of the trial is complete arteriovenous malformation occlusion, assessed by catheter cerebral angiography. Complete occlusions will be confirmed at 3 months, while incompletely occluded arteriovenous malformations, considered treatment failures, will then be eligible for complementary treatments by surgery, radiation therapy, or even transvenous embolisation. Standard procedural safety outcomes will also be assessed. Patient selection will be validated by a case selection committee, and participating centres with limited experience in transvenous embolisation will be proctored. Discussion The TATAM trial is a transparent research framework designed to offer a promising but still unvalidated treatment to selected arteriovenous malformation patients. Clinical Trial Registration-URL: http://www.clinicaltrials.gov . Unique identifier: NCT03691870.

Sign in / Sign up

Export Citation Format

Share Document